Skip to main content

Posts

Showing posts with the label Pharmaceuticals

Featured Post

Market Daily Report: Bursa Malaysia Ends Nearly Flat As Construction Stocks Attract Buying

 KUALA LUMPUR, Sept 8 (Bernama) -- Bursa Malaysia closed almost flat on Tuesday as buying interest rotated away from index heavyweights towards smaller-cap construction stocks, with sentiment affected by geopolitical uncertainty, said an analyst. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) eased 0.39 of a point to 1,714.40 from Monday’s close of 1,714.79. The benchmark index opened 1.65 points lower at 1,713.14 and moved between 1,710.44 and 1,714.50 throughout the trading session. The broader market was almost evenly balanced, with decliners leading gainers 548 to 546, while 598 counters were unchanged, 1,107 were untraded and 25 were suspended. Turnover expanded to 4.13 billion units valued at RM3.14 billion from 3.60 billion units valued at RM2.45 billion on Monday.

Trump Unveils New Tariffs on Pharmaceuticals, Building Materials, and Trucks

Sweeping Import Duties Effective Oct 1 President Donald Trump announced a fresh round of tariffs that will take effect on  Oct 1 , targeting a wide range of imported goods including pharmaceuticals, building materials, furniture, and heavy trucks. Pharmaceuticals Face 100% Tariff Unless Produced in U.S. Under the new measures,  branded and patented drugs  will face  100% duties  unless their manufacturers have already started or are in the process of building production facilities in the United States. Companies with U.S. facilities under construction will be exempt from the new levy. Trump did not specify under which authority the tariffs are being imposed. Building Materials and Furniture Hit With 50%–30% Tariffs Imported  kitchen cabinets, bathroom vanities, and related products  will face  50% tariffs , while  upholstered furniture  will be subject to  30% tariffs . Trump claimed that foreign suppliers have been “flooding” the U...

The Silent Compounder: Why Harbin Pharma (SHSE:600664) May Be Just Getting Started

Not all rallies scream with hype. Some, like  Harbin Pharmaceutical Group , climb quietly — backed not by noise, but by  solid fundamentals . +11% in the past month. 57% earnings growth over five years. ROE of 11% vs. industry average of 7.1%. These aren’t meme metrics — these are the  hallmarks of a business executing well  behind the scenes. What’s Driving It? Efficient capital use : For every ¥1 in equity, Harbin Pharma returns ¥0.11 in profit. Reinvesting 100%  of its earnings. No dividends. Just pure business reinvestment. Outpaced its industry : While peers averaged 6.2% net income growth, Harbin clocked in 57%. That’s the kind of compounding investors dream of — and rarely find without digging. But Here’s the Twist… Analysts expect earnings growth to  slow down . Whether that’s a sector-wide sentiment shift or a real red flag depends on how well management can continue allocating capital effectively. Stock Picker’s Take: This is a  “sleep well a...